Chardan Capital keeps Buy on Rocket Pharmaceuticals, sets $11 target
Chardan Capital maintained its Buy rating on Rocket Pharmaceuticals and reiterated a $11.00 price target.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.